ENTRY       D10501            Mixture   Drug
NAME        Fluticasone furoate and vilanterol trifenatate;
            Breo ellipta (TN);
            Relvar ellipita (TN)
PRODUCT     BREO ELLIPTA (GlaxoSmithKline LLC)
  GENERIC   FLUTICASONE FUROATE AND VILANTEROL (Prasco Laboratories)
COMPONENT   Fluticasone furoate [DR:D06315], (Vilanterol trifenatate [DR:D09697] | Vilanterol [DR:D09696])
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2290
            ATC code: R03AK10
            Product: D10501<JP/US>
EFFICACY    Antiasthmatic
  DISEASE   Chronic obstructive pulmonary disease [DS:H01714]
            Asthma [DS:H00079]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03A ADRENERGICS, INHALANTS
                R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
                 R03AK10 Vilanterol and fluticasone furoate
                  D10501  Fluticasone furoate and vilanterol trifenatate &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Bronchodilator Combinations
               Fluticasone Furoate/ Vilanterol Trifenatate
                D10501  Fluticasone furoate and vilanterol trifenatate
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D10501  Fluticasone furoate and vilanterol trifenatate
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10501  Fluticasone furoate and vilanterol trifenatate
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10501
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10501
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10501
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10501
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10501
DBLINKS     PubChem: 172232594
///
